Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mony reiterates outlook despite market headwinds

(Sharecast News) - MoneySuperMarket-owner Mony Group reiterated its full-year guidance on Monday, despite ongoing weakness in the car insurance market. Group revenues in the six months to 30 June nudged up just 1%, to £225.3m, while adjusted earnings before interest, tax, depreciation and amortisation rose 2% at £75.1m.

Within individual divisions, revenues in money were 4% higher, at £52.8m, and up 29% in home services, at £21.6m.

But in insurance, its biggest sector by some distance, revenues fell 2% to £117.7m. While home insurance premiums rose 4%, they slid 9% in motor, contributing to a 2% decline in car insurance revenues.

The cashback division also struggled, with revenues 9% lower at £27.2m.

However, looking to the full year and the FTSE 250 group said it remained on track to meet consensus for adjusted EBITDA of £143.7m.

"Despite the headwinds faced in some of our end markets, we continue to leverage our strength in breadth and the agility of our platform to deliver resilient financial performance while maintaining strategic momentum," Mony said.

Chief executive Peter Duffy added: "We are rolling out new AI-assisted customer experiences in insurance, credit cards and energy, and we've launched multiple products during the half focused on new, profitability growth opportunities, such as our new life insurance offer.

"We have a clean balance sheet, maintain an active pipeline of M&A opportunities and are well placed to deliver further value for our shareholders."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.